MedTrace Logo

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

NCT04425382 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-08-16

No results posted yet for this study

Summary

Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health.

Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects.

The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.

Conditions

Interventions

DRUG

Darunavir/Cobicistat

Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily

DRUG

Lopinavir/Ritonavir

Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily

Sponsors & Collaborators

  • Hamad Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Dr. Eman Elmekaty, PharmD · Hamad Medical Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-07-31
Completion
2020-09-30
FDA Drug
Yes

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425382 on ClinicalTrials.gov